Press coverage about Bruker (NASDAQ:BRKR) has trended somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Bruker earned a news impact score of 0.18 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 46.0744535228934 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- BidaskClub Upgrades Bruker (BRKR) to “Buy” (americanbankingnews.com)
- Bruker (BRKR) Receives Average Rating of “Hold” from Analysts (americanbankingnews.com)
- $419.95 Million in Sales Expected for Bruker (BRKR) This Quarter (americanbankingnews.com)
- Zacks: Brokerages Anticipate Bruker Co. (BRKR) Will Post Earnings of $0.23 Per Share (americanbankingnews.com)
- Analyzing Waters (WAT) & Bruker (BRKR) (americanbankingnews.com)
A number of equities analysts have recently commented on the company. BidaskClub raised Bruker from a “hold” rating to a “buy” rating in a research report on Friday. Leerink Swann boosted their price objective on Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a research report on Friday, February 9th. BTIG Research assumed coverage on Bruker in a research report on Friday, January 5th. They set a “buy” rating and a $42.00 price objective for the company. Morgan Stanley lowered their price objective on Bruker from $35.00 to $32.00 and set an “equal weight” rating for the company in a research report on Friday, February 9th. Finally, Zacks Investment Research raised Bruker from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a report on Thursday, January 4th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and four have issued a buy rating to the company’s stock. Bruker currently has a consensus rating of “Hold” and a consensus price target of $32.62.
Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 8th. The medical research company reported $0.51 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.49 by $0.02. Bruker had a return on equity of 26.68% and a net margin of 4.45%. The company had revenue of $530.50 million during the quarter, compared to analysts’ expectations of $506.74 million. During the same quarter in the previous year, the business earned $0.46 earnings per share. The firm’s revenue for the quarter was up 12.8% on a year-over-year basis. equities analysts anticipate that Bruker will post 1.37 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, March 23rd. Shareholders of record on Tuesday, March 6th were paid a $0.04 dividend. This represents a $0.16 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date was Monday, March 5th. Bruker’s dividend payout ratio is currently 13.22%.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/04/06/bruker-brkr-given-news-sentiment-score-of-0-18/2034842.html.
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions worldwide. The company operates through two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear and explosive detection in emergency response, homeland security, and defense applications; and analytical and process analysis instruments and solutions.
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.